Literature DB >> 12822606

Factors predictive of complete resection of operable esophageal cancer: a prospective study.

Christophe Mariette1, Laetitia Finzi, Sylvain Fabre, Jean-Michel Balon, Isabelle Van Seuningen, Jean-Pierre J Triboulet.   

Abstract

BACKGROUND: Esophagectomy remains a standard treatment for patients with resectable esophageal cancer, but the 5-year survival is only 20% to 25%. After complete resection survival is significantly longer than after incomplete resection with microscopic or macroscopic penetration. The purpose of this study was to prospectively identify the factors predictive of complete resection of operable esophageal cancers.
METHODS: Betwen January 1995 and January 2002, 372 patients with esophageal cancer underwent surgery with curative intent. Complete resection was performed in 304 patients (81.7%), incomplete resection with microscopic penetration in 28 (7.5%), and incomplete resection with macroscopic penetration in 40 (10.8%). Univariate and multivariate analysis included 16 preoperative and operative factors.
RESULTS: Factors predictive of complete resection were absence of any modification of the esophageal axis on the barium swallow (p = 0.019) and a partial or complete response to preoperative radiochemotherapy (p = 0.042). Three groups of patients were identified: group 1 had no deviation of the axis on the barium swallow (n = 253); group 2 had deviation of the axis on the barium swallow and partial or complete response to radiochemotherapy (n = 66); and group 3 had deviation of the axis on the barium swallow and no response to radiochemotherapy or no preoperative treatment (n = 53). Rates of complete resection were 90.1%, 74.2%, and 50.9%, and 5-year actuarial survivals were 46%, 37%, and 0%, respectively (p < 0.001).
CONCLUSIONS: Complete resection of esophageal cancer is predictable. Deviation axis on the barium swallow and morphologic response to neoadjuvant radiochemotherapy are variables available for all patients at onset of therapeutic management.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12822606     DOI: 10.1016/s0003-4975(03)00172-3

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  7 in total

1.  The Role of Adjuvant Therapy in Patients With Margin-Positive (R1) Esophagectomy: A National Analysis.

Authors:  Vignesh Raman; Oliver K Jawitz; Soraya L Voigt; Chi-Fu J Yang; Thomas A D'Amico; David H Harpole
Journal:  J Surg Res       Date:  2020-01-08       Impact factor: 2.192

2.  A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer.

Authors:  F De Vita; M Orditura; E Martinelli; L Vecchione; R Innocenti; V C Sileni; C Pinto; M Di Maio; A Farella; T Troiani; F Morgillo; V Napolitano; E Ancona; N Di Martino; A Ruol; G Galizia; A Del Genio; F Ciardiello
Journal:  Br J Cancer       Date:  2011-01-18       Impact factor: 7.640

Review 3.  Postoperative radiation in esophageal squamous cell carcinoma and target volume delineation.

Authors:  Yingming Zhu; Minghuan Li; Li Kong; Jinming Yu
Journal:  Onco Targets Ther       Date:  2016-07-11       Impact factor: 4.147

4.  Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or the gastroesophageal junction: A meta-analysis based on clinical trials.

Authors:  Xin Zhao; Yiming Ren; Yong Hu; Naiqiang Cui; Ximo Wang; Yunfeng Cui
Journal:  PLoS One       Date:  2018-08-23       Impact factor: 3.240

5.  circGSK3β promotes metastasis in esophageal squamous cell carcinoma by augmenting β-catenin signaling.

Authors:  Xueting Hu; Duoguang Wu; Xiaotian He; Huiying Zhao; Zhanghai He; Jiatong Lin; Kefeng Wang; Wenjian Wang; Zihao Pan; Huayue Lin; Minghui Wang
Journal:  Mol Cancer       Date:  2019-11-14       Impact factor: 27.401

6.  LPCAT1 reprogramming cholesterol metabolism promotes the progression of esophageal squamous cell carcinoma.

Authors:  Mingyue Tao; Jing Luo; Tong Gu; Xiaojuan Yu; Zhen Song; Yali Jun; Hao Gu; Kairong Han; Xiujuan Huang; Weiyong Yu; Su'an Sun; Zhengwei Zhang; Lu Liu; Xiaofei Chen; Li Zhang; Chao Luo; Qilong Wang
Journal:  Cell Death Dis       Date:  2021-09-13       Impact factor: 8.469

7.  Neoadjuvant continuous infusion of weekly 5-fluorouracil and escalating doses of oxaliplatin plus concurrent radiation in locally advanced oesophageal squamous cell carcinoma: results of a phase I/II trial.

Authors:  S Lorenzen; B Brücher; F Zimmermann; H Geinitz; J Riera; T Schuster; N Roethling; H Höfler; K Ott; C Peschel; J R Siewert; M Molls; F Lordick
Journal:  Br J Cancer       Date:  2008-09-16       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.